Skip to main content
Clinical Trials/CTRI/2020/05/025270
CTRI/2020/05/025270Not yet recruiting未知

Effect of intravenous Azithromycin as adjunctive empirical treatment in children with acute encephalitis syndrome

KUNDAN MITTA0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Presence of altered mental status with at least three of the following: fever ( >38 C) lasting for more than 72 hours before or after presentation; generalized or focal seizure not attributable to preexisting seizure disorder; new onset of focal neurological deficit; CSF pleocytosis > 5/cumm; abnormality of brain parenchyma on neuro imaging suggestive of encephalitis that is acute in onset or new from prior studies; abnormality on electroencephalography that is consistent with encephalitis and not attributable to another cause, coma, or inability to talk.

Exclusion Criteria

  • - Children with prior developmental delay or intellectual disability
  • - Children with known renal, pulmonary, cardiac or hepatic dysfunction.
  • - Children with suspected inborn errors of metabolism
  • - Children with toxic encephalopathy or traumatic brain injury
  • - Children who have hemorrhagic or ischemic stroke
  • - Children with clinical and laboratory evidence of multi-organ dysfunction at hospital admission
  • - Children who have already received treatment other than conventional treatment including Azithromycin or steroids
  • - Children having high clinical suspicion of bacterial meningitis or TB meningitis
  • - Children with a contraindication to Azithromycin or albumin
  • - Children with known hyper coagulable state

Investigators

Sponsor
KUNDAN MITTA

Similar Trials